In relation to access to treatment for rarer cancers, the SMC has a standard process for assessing all newly licensed medicines. The process for assessing orphan medicines, as defined by the European Medicines Agency as a medicine licensed to treat or prevent life-threatening rare diseases affecting fewer than five in 10,000 people in the European Union, is the same as for all other medicines.